Key clinical point: Study provides further evidence that DAA treatment has non–liver related benefits.
Major finding: DAA treatment was linked to lower diabetes incidence (HR, 0.48).
Study details: Propensity-matched, retrospective analysis (26,043 pairs).
Disclosures: The study was funded by Gilead. Dr. Butt has had research grants from Gilead and Dr. Schooley is on Gilead’s scientific advisory board.
A Butt et al. CROI 2019. Abstract 88.